Blog
About

0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Hemodynamic and Neurohumoral Effects of Ibopamine in Patients with Chronic Congestive Heart Failure

      Cardiology

      S. Karger AG

      Ibopamine, Hemodynamic and neurohumoral effects, Chronic congestive heart failure

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Ibopamine is a new, orally active dopamine-like drug with inotropic and vasoac-tive properties. With a predominant action on dopaminergic (DA) and β-receptors, ibopamine increases cardiac output, reduces peripheral vascular resistances and increases renal blood flow, exerting a lesser effect on preload parameters. This hemodynamic improvement is manifested in subjects with normal myocardium as well as in patients with heart failure in different stages of the syndrome including refractory heart failure, and it is also present after relatively long-term treatment without evidence of pharmacological tolerance. Probably in relation with DA<sub>2</sub> activation, ibopamine also modulates the neurohumoral consequences of heart failure with a decrease in plasma renin activity and norepinephrine and aldosterone plasma levels, both acutely and after chronic administration, an effect that can be beneficial in the long-term treatment of patients with chronic congestive heart failure.

          Related collections

          Author and article information

          Journal
          CRD
          Cardiology
          10.1159/issn.0008-6312
          Cardiology
          S. Karger AG
          978-3-8055-5309-4
          978-3-318-01566-9
          0008-6312
          1421-9751
          1990
          1990
          12 November 2008
          : 77
          : Suppl 5
          : 9-21
          Affiliations
          Servicio de Coronariopatías, Unidad Coronaria, Hospital La Paz, Madrid, Spain
          Article
          174690 Cardiology 1990;77:9–21
          10.1159/000174690
          1980634
          © 1990 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 13
          Categories
          Ibopamine in the Management of Congestive Heart Failure

          Comments

          Comment on this article